On 8, Spyre Therapeutics (NASDAQ:SYRE) announced that SPY003, its anti-IL-23 antibody, hit its primary endpoint in Part A of ...

Spyre Therapeutics, Inc. (NASDAQ:SYRE) reported September 8 results from 44 patients with moderately to severely active ...

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a ...

Shares of Spyre Therapeutics SYRE have surged 73% over the past month after the company reported encouraging data from a mid-stage study evaluating its investigational anti-α4β7 drug, SPY001, in ...

While "the trend is your friend" when it comes to short-term investing or trading, timing entries into the trend is a key determinant of success. And increasing the odds of success by making sure the ...

) has been revised to $88.06 / share. This is an increase of 42.03% from the prior estimate of $62.00 dated April 12, 2026. The price target is an average of many targets provided by analysts. The ...

Swedish textile startup Syre AB plans to raise as much as $700 million in fresh funding to build a factory in Vietnam, following a supply deal with Nike Inc. that it says will help unlock new ...